Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (41-50 of 525) with videos related to

Pageof 53
Sort By:
Vitamins and Hormones|March 7, 2012
Canonical and noncanonical Hedgehog/GLI signaling in hematological malignanciesFritz Aberger, Daniela Kern, Richard Greil, et al.
Nature Reviews. Clinical Oncology|June 3, 2009
Molecular and cellular mechanisms of CLL: novel therapeutic approachesLisa Pleyer, Alexander Egle, Tanja Nicole Hartmann, et al.
Memo|September 18, 2018
Cure in metastatic breast cancerTheresa Westphal, Simon Peter Gampenrieder, Gabriel Rinnerthaler, et al.
Clinical Breast Cancer|November 20, 2013
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?Florian Huemer, Simon Peter Gampenrieder, Alexander Schlattau, et al.
Cancer Management and Research|November 5, 2020
Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment OptionsSimon Peter Gampenrieder, Vanessa Castagnaviz, Gabriel Rinnerthaler, et al.
Cell Communication and Signaling : CCS|January 20, 2017
Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulationRichard Greil, Evelyn Hutterer, Tanja Nicole Hartmann, et al.
Molecular Cancer Therapeutics|June 30, 2011
Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological toolsOlaf Merkel, Frank Hamacher, Eveline Sifft, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 27, 2006
A role of TRAIL in killing osteoblasts by myeloma cellsInge Tinhofer, Rainer Biedermann, Martin Krismer, et al.
European Journal of Haematology|January 3, 2013
A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17pKonrad Namberger, Lukas Weiss, Barbara Krause, et al.
Expert Opinion on Investigational Drugs|February 14, 2024
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trialsDominik Kiem, Matthias Ocker, Richard Greil, et al.
Pageof 53

Showing results (41-50 of 525) with videos related to

Sort By:
Pageof 53
Vitamins and Hormones|March 7, 2012
Canonical and noncanonical Hedgehog/GLI signaling in hematological malignanciesFritz Aberger, Daniela Kern, Richard Greil, et al.
Nature Reviews. Clinical Oncology|June 3, 2009
Molecular and cellular mechanisms of CLL: novel therapeutic approachesLisa Pleyer, Alexander Egle, Tanja Nicole Hartmann, et al.
Memo|September 18, 2018
Cure in metastatic breast cancerTheresa Westphal, Simon Peter Gampenrieder, Gabriel Rinnerthaler, et al.
Clinical Breast Cancer|November 20, 2013
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?Florian Huemer, Simon Peter Gampenrieder, Alexander Schlattau, et al.
Cancer Management and Research|November 5, 2020
Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment OptionsSimon Peter Gampenrieder, Vanessa Castagnaviz, Gabriel Rinnerthaler, et al.
Cell Communication and Signaling : CCS|January 20, 2017
Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulationRichard Greil, Evelyn Hutterer, Tanja Nicole Hartmann, et al.
Molecular Cancer Therapeutics|June 30, 2011
Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological toolsOlaf Merkel, Frank Hamacher, Eveline Sifft, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 27, 2006
A role of TRAIL in killing osteoblasts by myeloma cellsInge Tinhofer, Rainer Biedermann, Martin Krismer, et al.
European Journal of Haematology|January 3, 2013
A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17pKonrad Namberger, Lukas Weiss, Barbara Krause, et al.
Expert Opinion on Investigational Drugs|February 14, 2024
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trialsDominik Kiem, Matthias Ocker, Richard Greil, et al.
Pageof 53